A Case of Erythrodermic Psoriasis Successfully Treated with Risankizumab

References

• Boehncke WH, Schön MP. Psoriasis. Lancet. 2015;386(9997):983–994. doi:10.1016/S0140-6736(14)61909-7
   PubMed Web of Science ®Google Scholar
• Langley RGB, Krueger GG, Griffiths CEM. Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis. 2005;64(Suppl 2):ii18–ii23; discussion ii24–ii25. doi:10.1136/ard.2004.033217
   PubMedGoogle Scholar
• Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet. 2007;370(9583):263–271. doi:10.1016/S0140-6736(07)61128-3
   PubMed Web of Science ®Google Scholar
• Shao S, Wang G, Maverakis E, Gudjonsson JE. Targeted treatment for erythrodermic psoriasis: rationale and recent advances. Drugs. 2020;80(6):525–534. doi:10.1007/s40265-020-01283-2
   PubMed Web of Science ®Google Scholar
• Lo Y, Tsai TF. Updates on the Treatment of Erythrodermic Psoriasis. Psoriasis. 2021;11:59–73. doi:10.2147/PTT.S288345
   PubMed Web of Science ®Google Scholar
• Potestio L, Camela E, Cacciapuoti S, et al. Biologics for the management of erythrodermic psoriasis: an updated review. Clin Cosmet Investig Dermatol. 2023;16:2045–2059. doi:10.2147/CCID.S407813
   PubMed Web of Science ®Google Scholar
• Dogra S, Mehta H. Biological treatment for erythrodermic psoriasis. Expert Opin Biol Ther. 2022;22(12):1531–1543. doi:10.1080/14712598.2022.2128669
   PubMed Web of Science ®Google Scholar
• Camela E, Potestio L, Fabbrocini G, Pallotta S, Megna M. The holistic approach to psoriasis patients with comorbidities: the role of investigational drugs. Expert Opin Investig Drugs. 2023;1–16. doi:10.1080/13543784.2023.2219387
   PubMed Web of Science ®Google Scholar
• Megna M, Camela E, Battista T, et al. Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part II: focus on elderly patients. Expert Opin Drug Saf. 2023:1–16. doi:10.1080/14740338.2023.2173171
   PubMed Web of Science ®Google Scholar
• Megna M, Camela E, Battista T, et al. Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part I: focus on pediatric patients. Expert Opin Drug Saf. 2023;22(1):25–41. doi:10.1080/14740338.2023.2173170
   PubMed Web of Science ®Google Scholar
• Nast A, Smith C, Spuls PI, et al. EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris - Part 1: treatment and monitoring recommendations. J Eur Acad Dermatol Venereol. 2020;34(11):2461–2498. doi:10.1111/jdv.16915
   PubMed Web of Science ®Google Scholar
• Nast A, Smith C, Spuls PI, et al. EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris - Part 2: specific clinical and comorbid situations. J Eur Acad Dermatol Venereol. 2021;35(2):281–317. doi:10.1111/jdv.16926
   PubMed Web of Science ®Google Scholar
• Megna M, Battista T, Potestio L, et al. A case of erythrodermic psoriasis rapidly and successfully treated with Bimekizumab. J Cosmet Dermatol. 2023;22(3):1146–1148. doi:10.1111/jocd.15543
   PubMed Web of Science ®Google Scholar
• Megna M, Potestio L, Fabbrocini G, Cinelli E. Tildrakizumab: a new therapeutic option for erythrodermic psoriasis? Dermatol Ther. 2021;34(5):e15030. doi:10.1111/dth.15030
   PubMed Web of Science ®Google Scholar
• Gu C, Yang J. Risankizumab for the treatment of psoriasis. Expert Rev Clin Pharmacol. 2019;12(9):851–857. doi:10.1080/17512433.2019.1657829
   PubMed Web of Science ®Google Scholar
• Gordon KB, Lebwohl M, Papp KA, et al. Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2022;186(3):466–475. doi:10.1111/bjd.20818
   PubMed Web of Science ®Google Scholar
• Megna M, Ruggiero A, Battista T, Marano L, Cacciapuoti S, Potestio L. Long-term efficacy and safety of risankizumab for moderate to severe psoriasis: a 2-year real-life retrospective study. J Clin Med. 2023;12(9):3233. doi:10.3390/jcm12093233
   PubMed Web of Science ®Google Scholar
• Jiang Y, Chen Y, Yu Q, Shi Y. Biologic and small-molecule therapies for moderate-to-severe psoriasis: focus on psoriasis comorbidities. BioDrugs. 2023;37(1):35–55. doi:10.1007/s40259-022-00569-z
   PubMed Web of Science ®Google Scholar
• Ruggiero A, Camela E, Potestio L, Fabbrocini G, Megna M. Drug safety evaluation of tildrakizumab for psoriasis: a review of the current knowledge. Expert Opin Drug Saf. 2022;21(12):1445–1451. doi:10.1080/14740338.2022.2160447
   PubMed Web of Science ®Google Scholar
• Ruggiero A, Potestio L, Cacciapuoti S, et al. Tildrakizumab for the treatment of moderate to severe psoriasis: results from a single center preliminary real-life study. Dermatol Ther. 2022;35(12):e15941. doi:10.1111/dth.15941
   PubMed Web of Science ®Google Scholar
• Yamanaka K, Okubo Y, Yasuda I, Saito N, Messina I, Morita A. Efficacy and safety of risankizumab in Japanese patients with generalized pustular psoriasis or erythrodermic psoriasis: primary analysis and 180-week follow-up results from the phase 3, multicenter IMMspire study. J Dermatol. 2023;50(2):195–202. doi:10.1111/1346-8138.16667
   PubMed Web of Science ®Google Scholar
• Alajlan A, Madani A, Qadoumi TA, Aljaloud A, Alessa M. Erythrodermic Psoriasis Managed with Risankizumab. Case Rep Dermatol. 2022;14(2):219–224. doi:10.1159/000525774
   PubMed Web of Science ®Google Scholar
• Martora F, Villani A, Battista T, Fabbrocini G, Potestio L. COVID-19 vaccination and inflammatory skin diseases. J Cosmet Dermatol. 2023;22(1):32–33. doi:10.1111/jocd.15414
   PubMed Web of Science ®Google Scholar
• Martora F, Villani A, Marasca C, Fabbrocini G, Potestio L. Skin reaction after SARS-CoV-2 vaccines Reply to “cutaneous adverse reactions following SARS-CoV-2 vaccine booster dose: a real-life multicentre experience”. J Eur Acad Dermatol Venereol. 2023;37(1):e43–e44. doi:10.1111/jdv.18531
   PubMed Web of Science ®Google Scholar
• Megna M, Potestio L, Battista T, et al. Immune response to Covid-19 mRNA vaccination in psoriasis patients undergoing treatment with biologics. Clin Exp Dermatol. 2022;47(12):2310–2312. doi:10.1111/ced.15395
   PubMed Web of Science ®Google Scholar